Dominion Diagnostics Introduces CARDâ„¢: The Next-Generation Clinical Laboratory Diagnostics Tool for Addiction Treatment
NORTH KINGSTOWN, R.I., June 15 /PRNewswire/ -- At the forefront of the ongoing effort to enhance addiction treatment outcomes, one leading Rhode Island Company has announced the next-generation clinical laboratory diagnostics tool designed to assist clinicians.
Dominion Diagnostics (Dominion), a privately-held clinical urine drug testing laboratory, today announced the release of its new Comprehensive Analysis of Reported Drugs (CARD)™ results, a unique clinical laboratory reporting service that provides clinicians with accurate testing results and analytical feedback to augment the assessment and monitoring of an individual's drug use upon admission and throughout the course of addiction treatment.
Dominion developed its CARD™ reporting service to create a highly personalized clinical report by correlating an individual's prescribed medication use and self-reported drug misuse with its state-of-the-art diagnostic testing.
CARD™ utilizes laboratory results from validated quantitative urine drug testing profiles for commonly abused illicit and prescription drugs and/or their metabolites, as well as biological markers and commercial adulterant screening (i.e., creatinine, specific gravity, pH, and oxidants) to ensure specimen validity. CARD™ employs a supplied list of prescribed treatment-related medications and self-reported non-prescribed drug misuse, along with documented pharmaceutical and pharmacokinetic references backed by Dominion's expert Clinical Services team of pharmacists.
Dominion's CARD™ results provide data to support and measure a treatment program's ability to reduce morbidity in substance abuse, improve retention in treatment, and promote the use of evi